Stock LSTA LISATA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Lisata Therapeutics, Inc.

Equities

LSTA

US1280583022

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-07 EDT 		5-day change 1st Jan Change
2.75 USD -0.72% Intraday chart for Lisata Therapeutics, Inc. -3.62% +0.73%
04-23 Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer MT
04-23 Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
GL
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
AQ
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
GL
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
AQ
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
AQ
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors
AQ
Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer
MT
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
GL
Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
CI
Lisata Therapeutics, Inc. Appoints James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer
CI
Transcript : Lisata Therapeutics, Inc. - Special Call
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
GL
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
CI
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
GL
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
MT
Sector Update: Health Care Stocks Higher in Afternoon Trading
MT
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug
MT
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
GL
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ
AQ
Transcript : Lisata Therapeutics, Inc., 2023 Earnings Call, Feb 29, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LSTA Stock
  4. News Lisata Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW